Celyad Oncology SA (CYAD) Issues Q4 Business Update and 2023 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook
February 3, 2023 1:00 AM ESTCelyad Oncology has implemented a strategic shift from an organization focused on clinical development to one fully harnessing the true potential of its proprietary technology platforms and intellectual property
The company is now prioritizing internal discovery endeavors to tackle the major current limitations of CAR T-cell therapiesAs of December 31, 2022, the Company ended the year with an unaudited treasury position of 12.4 million ($13.3 million)MONT-SAINT-GUIBERT, Belgium, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the Company), a biotechnology company focused on... More
